

Anti-NaPi2b/SLC34A2 Antibody (Lifastuzumab)

Introduction

Lifastuzumab is a humanized NaPi2b Monoclonal antibody (IgG1 type). Lifastuzumab can be used ADC Linker With monomethylauristatin E (MMAE) coupling to form the antibody-drug conjugate (ADC) Lifastuzumab vedotin (DNIB0600A) with anti-cancer activity.

Product parameters

Alternative Names	Lifastuzumab
Target Accession	O95436
Target	NaPi2b / SLC34A2
CAS number	1615697-16-9
Molecular Weight	145.66 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Human NaPi2b HEK293 Cell Line were stained with Anti-NaPi2b / SLC34A2 Reference Antibody (lifastuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 1.585 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

